Haemophilia : the official journal of the World Federation of Hemophilia · 2026
Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beserra Nathália Martins, Camelo Ricardo Mesquita, Sacramento Alice Oliver Rosa, Nascimento Eliziane Souza, Machado Rosângela Pinheiro Gonçalves, Gonçalves Machado Clarissa Maria, Dantas Suzzy Maria Carvalho, Rocha Samuel Gonçalves Machado da, Carvalho Luany Elvira Mesquita, Lemes Romélia Pinheiro Gonçalves
Аннотация
INTRODUCTION: Clotting factor prophylaxis remains the most prescribed standard-of-care treatment for people with haemophilia (PwH). Prophylaxis prevents bleeds, joint damage, and improves quality of life (QoL). Its success depends on treatment adherence, consisting of socioeconomic, behavioural, and disease- or therapy-related factors.
AIM: To identify determinants of clotting factor prophylaxis adherence among PwH followed at a Hemophilia Treatment Center (HTC) in Brazil.
METHODS: A cross-sectional study was conducted at a Brazilian HTC in June-October/2022. Eligible participants were PwH A or B without inhibitors and on clotting factor prophylaxis, aged ≥ 14 years. Demographic, clinical, and therapeutic data were collected from records and interviews. Health-related QoL was assessed by the SF-36 questionnaire. Adherence was assessed using the Brazilian validated Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro) questionnaire.
RESULTS: Among 78 PwH (median age 30 years), 70 (90%) had severe haemophilia, 46 (59%) reported joint impairment, and 67 (86%) infused 3 times/week. Median SF-36 score was 70.3 (interquartile range [IQR] 57.3-83.3). Median VERITAS-Pro score was 44.0 (IQR 35.0-50.0), resulting in 70 (90%) adherent PwH. SF-36 score was not correlated with VERITAS-Pro. Clotting factor prophylaxis adherence was associated with having haemophilia A (p = 0.012) and infusing factor >2 times weekly (p = 0.008), and inversely correlated with prophylaxis duration (r = 0.317 [weak clinical correlation]; p = 0.005), and directly correlated with SF-36 domain "Mental health" (r = -0.304 [weak clinical correlation]; p = 0.007).
CONCLUSION: The main factors determining adherence to clotting factor prophylaxis were having haemophilia A, receiving factor infusions more than twice weekly, having a shorter duration of prophylaxis, and good mental health.
AIM: To identify determinants of clotting factor prophylaxis adherence among PwH followed at a Hemophilia Treatment Center (HTC) in Brazil.
METHODS: A cross-sectional study was conducted at a Brazilian HTC in June-October/2022. Eligible participants were PwH A or B without inhibitors and on clotting factor prophylaxis, aged ≥ 14 years. Demographic, clinical, and therapeutic data were collected from records and interviews. Health-related QoL was assessed by the SF-36 questionnaire. Adherence was assessed using the Brazilian validated Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro) questionnaire.
RESULTS: Among 78 PwH (median age 30 years), 70 (90%) had severe haemophilia, 46 (59%) reported joint impairment, and 67 (86%) infused 3 times/week. Median SF-36 score was 70.3 (interquartile range [IQR] 57.3-83.3). Median VERITAS-Pro score was 44.0 (IQR 35.0-50.0), resulting in 70 (90%) adherent PwH. SF-36 score was not correlated with VERITAS-Pro. Clotting factor prophylaxis adherence was associated with having haemophilia A (p = 0.012) and infusing factor >2 times weekly (p = 0.008), and inversely correlated with prophylaxis duration (r = 0.317 [weak clinical correlation]; p = 0.005), and directly correlated with SF-36 domain "Mental health" (r = -0.304 [weak clinical correlation]; p = 0.007).
CONCLUSION: The main factors determining adherence to clotting factor prophylaxis were having haemophilia A, receiving factor infusions more than twice weekly, having a shorter duration of prophylaxis, and good mental health.